Biotechnology Engineering: Expected to Lean Heavily on AI/ML and Big Data in 2024

Advanced technologies are pushing biotechnology engineering in new directions.

As a result, there will continue to be an increase in consumer biotech or biotechnology products targeted directly at customers instead of biopharma or healthcare businesses.

Startups in the emerging biotechnology engineering realm are starting to focus on solutions other than those in medicine – everything from food and materials to environmental monitoring. Still, 2024 and beyond will continue to see biotech innovation primarily in the medical/health fields.

Artificial intelligence, machine learning and Big Data are evolving technologies that help act as conduits for emerging biotechnology engineering enterprises.

Take Big Data. There is an unprecedented amount of data available in biotechnology today, from the ever-growing omics technologies and integration of sensors and the Internet of Things (IoT) devices.

Big data and analytics solutions allow biotechnology startups to tap into this wealth of data to drive innovation.

BioXplor, a German company, is using big data to develop better and safer treatment regimens. It uses network pharmacology to create treatments from disorganized and disparate data sources. The startup’s approach detects whether drug combinations have synergistic or antagonistic effects.

It also mines patient information for responder and non-responder signals to improve patient results and analyze treatment response.

Experts in this field contend that AI and machine learning (ML) in biotechnology will also be heavily leaned on in 2024.

AI's power lies in expediting drug discovery by analyzing expansive datasets from genomics, proteomics, and beyond, identifying promising drug targets and predicting their efficacy.

ML algorithms can facilitate the design of novel drug molecules with precise properties, optimizing potency while minimizing toxicity, thereby ushering in safer and more effective medications with reduced side effects.

Biotech companies will likely benefit from AI-driven drug repurposing strategies, leveraging data from clinical trials and patient records to unearth new applications for existing drugs, accelerating time-to-market for novel treatments in a cost-effective manner.

Want to learn more? Tonex offers Emerging Biotechnology Engineering, a 2-day course that introduces participants to the emerging engineering discipline of biotechnology. This course is especially beneficial for individuals and organizations who want to see the “big picture” in order to communicate with technical as well as non-technical individuals.

This short course covers the most important aspects of biotechnology without getting too involved in the technical nitty gritty.

Participants will learn how living systems are used to produce a wide range of technologies and capabilities.

For more information, questions, comments,?contact us.

?